These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36342853)

  • 1. Progressive Acceleration of Insulin Exposure Over 7 Days of Infusion Set Wear.
    Kastner JR; Bailey TS; Strange P; Shi L; Oberg KA; Strasma PJ; Joseph JI; Muchmore DB
    Diabetes Technol Ther; 2023 Feb; 25(2):143-147. PubMed ID: 36342853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility study of a prototype extended-wear insulin infusion set in adults with type 1 diabetes.
    Kastner JR; Venkatesh N; Brown K; Muchmore DB; Ekinci E; Fourlanos S; Joseph JI; Shafeeq M; Shi L; Strange P; Strasma PJ; O'Neal DN
    Diabetes Obes Metab; 2022 Jun; 24(6):1143-1149. PubMed ID: 35257468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Insulin Infusion Set in the New Era of Automated Insulin Delivery: A Systematic Review.
    Zhang G; Romo-Anselmo E; Kwa T; Cohen O; Vigersky R; Chattaraj S
    J Diabetes Sci Technol; 2023 Mar; 17(2):302-313. PubMed ID: 36562593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
    Heise T; Meiffren G; Alluis B; Seroussi C; Ranson A; Arrubla J; Correia J; Gaudier M; Soula O; Soula R; DeVries JH; Klein O; Bode B
    Diabetes Obes Metab; 2019 Apr; 21(4):1066-1070. PubMed ID: 30565407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes.
    Garhyan P; Pratt E; Klein O; Famulla S; Zijlstra E; Lalonde A; Swinney M; Kazda C; Dassau E
    J Diabetes Sci Technol; 2023 Mar; 17(2):274-282. PubMed ID: 36575993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival assessment of the extended-wear insulin infusion set featuring lantern technology in adults with type 1 diabetes by the glucose clamp technique.
    Simic A; Schøndorff PK; Stumpe T; Heschel M; Regittnig W; Pöttler T; Ninaus D; Augustin T; Groselj-Strele A; Pieber TR; Mader JK
    Diabetes Obes Metab; 2021 Jun; 23(6):1402-1408. PubMed ID: 33528887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin Requirements.
    Ma X; Benson CT; Prescilla R; Zhang S; Linnebjerg H; LaBell ES; Morrow LA; Jackson JA; Nguyen A; Ilag LL; Johnson JL; Leishman D
    J Diabetes Sci Technol; 2022 Mar; 16(2):401-407. PubMed ID: 33242998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes.
    Kapitza C; Nowotny I; Lehmann A; Bergmann K; Rotthaeuser B; Nosek L; Becker RHA
    Diabetes Obes Metab; 2017 May; 19(5):622-627. PubMed ID: 27987252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL.
    de la Peña A; Seger M; Soon D; Scott AJ; Reddy SR; Dobbins MA; Brown-Augsburger P; Linnebjerg H
    Clin Pharmacol Drug Dev; 2016 Jan; 5(1):69-75. PubMed ID: 27119580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo investigation of the tissue response to commercial Teflon insulin infusion sets in large swine for 14 days: the effect of angle of insertion on tissue histology and insulin spread within the subcutaneous tissue.
    Eisler G; Kastner JR; Torjman MC; Khalf A; Diaz D; Dinesen AR; Loeum C; Thakur ML; Strasma P; Joseph JI
    BMJ Open Diabetes Res Care; 2019; 7(1):e000881. PubMed ID: 31875136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longevity of the novel ConvaTec infusion set with Lantern technology.
    Lal RA; Hsu L; Zhang J; Schøndorff PK; Heschel M; Buckingham B
    Diabetes Obes Metab; 2021 Aug; 23(8):1973-1977. PubMed ID: 33822472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
    Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I
    Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248
    [No Abstract]   [Full Text] [Related]  

  • 14. Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device.
    Landau Z; Klonoff D; Nayberg I; Feldman D; Levit SB; Lender D; Mosenzon O; Raz I; Wainstein J
    Diabetes Metab Res Rev; 2014 Nov; 30(8):686-92. PubMed ID: 24610683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy.
    Swan KL; Dziura JD; Steil GM; Voskanyan GR; Sikes KA; Steffen AT; Martin ML; Tamborlane WV; Weinzimer SA
    Diabetes Care; 2009 Feb; 32(2):240-4. PubMed ID: 19017777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lispro administered by the QS-M Needle-Free Jet Injector generates an earlier insulin exposure.
    Hu J; Shi H; Zhao C; Li X; Wang Y; Cheng Q; Goswami R; Zhen Q; Mei M; Song Y; Yang S; Li Q
    Expert Opin Drug Deliv; 2016 Sep; 13(9):1203-7. PubMed ID: 27267431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump.
    Thrasher J; Surks H; Nowotny I; Pierre S; Rotthaeuser B; Wernicke-Panten K; Garg S
    J Diabetes Sci Technol; 2018 May; 12(3):680-686. PubMed ID: 29359575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
    Crutchlow MF; Palcza JS; Mostoller KM; Mahon CD; Barbour AM; Marcos MC; Xu Y; Watkins E; Morrow L; Hompesch M
    Diabetes Obes Metab; 2018 Feb; 20(2):400-408. PubMed ID: 28817223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial.
    Brazg R; Garg SK; Bhargava A; Thrasher JR; Latif K; Bode BW; Bailey TS; Horowitz BS; Cavale A; Kudva YC; Kaiserman KB; Grunberger G; Reed JC; Chattaraj S; Zhang G; Shin J; Chen V; Lee SW; Cordero TL; Rhinehart AS; Vigersky RA; Buckingham BA
    Diabetes Technol Ther; 2022 Aug; 24(8):535-543. PubMed ID: 35263188
    [No Abstract]   [Full Text] [Related]  

  • 20. Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion.
    Tiffner K; Boulgaropoulos B; Höfferer C; Birngruber T; Porksen N; Linnebjerg H; Garhyan P; Lam ECQ; Knadler MP; Pieber TR; Sinner F
    Diabetes Technol Ther; 2017 May; 19(5):305-314. PubMed ID: 28328234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.